Clinical trial

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

NCT02121717

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-06-01

PhasePHASE3

Study timeline

Study start (unknown)2014-06-01Date precision: month

Registry last updated2019-10-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Interventions

ChiglitazarDRUG

PlaceboDRUG

Sponsors & collaborators

Chipscreen Biosciences, Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China4 ShanghaiShanghai Municipality, China3 ChongqingChongqing Municipality, China3 NanjingJiangsu, China1 ChangshaHunan, China1 WuhanHubei, China1 ChengduSichuan, China1 TianjinTianjin Municipality, China1 ChangchunJilin, China1 HarbinHeilongjiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02121717 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.